BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1391937)

  • 1. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support.
    Jagannath S; Vesole DH; Glenn L; Crowley J; Barlogie B
    Blood; 1992 Oct; 80(7):1666-72. PubMed ID: 1391937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.
    Tricot G; Jagannath S; Vesole D; Nelson J; Tindle S; Miller L; Cheson B; Crowley J; Barlogie B
    Blood; 1995 Jan; 85(2):588-96. PubMed ID: 7529066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
    Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
    Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.
    Elias AD; Ayash L; Anderson KC; Hunt M; Wheeler C; Schwartz G; Tepler I; Mazanet R; Lynch C; Pap S
    Blood; 1992 Jun; 79(11):3036-44. PubMed ID: 1350229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma.
    Barlogie B; Jagannath S; Dixon DO; Cheson B; Smallwood L; Hendrickson A; Purvis JD; Bonnem E; Alexanian R
    Blood; 1990 Aug; 76(4):677-80. PubMed ID: 2200536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation.
    Rosenfeld CS; Gremba C; Shadduck RK; Zeigler ZR; Nemunaitis J
    Exp Hematol; 1994 Mar; 22(3):290-4. PubMed ID: 7509292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma.
    Awedan AA
    Ann Transplant; 2002; 7(2):38-43. PubMed ID: 12416471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.
    Desikan KR; Barlogie B; Jagannath S; Vesole DH; Siegel D; Fassas A; Munshi N; Singhal S; Mehta J; Tindle S; Nelson J; Bracy D; Mattox S; Tricot G
    J Clin Oncol; 1998 Apr; 16(4):1547-53. PubMed ID: 9552064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma.
    Tricot G; Gazitt Y; Leemhuis T; Jagannath S; Desikan KR; Siegel D; Fassas A; Tindle S; Nelson J; Juttner C; Tsukamoto A; Hallagan J; Atkinson K; Reading C; Hoffman R; Barlogie B
    Blood; 1998 Jun; 91(12):4489-95. PubMed ID: 9616143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.
    Spitzer G; Adkins D; Mathews M; Velasquez W; Bowers C; Dunphy F; Kronmueller N; Niemeyer R; McIntyre W; Petruska P
    Bone Marrow Transplant; 1997 Dec; 20(11):921-30. PubMed ID: 9422470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization.
    Watts MJ; Sullivan AM; Leverett D; Peniket AJ; Perry AR; Williams CD; Devereux S; Goldstone AH; Linch DC
    J Clin Oncol; 1998 Apr; 16(4):1554-60. PubMed ID: 9552065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma.
    Advani R; Chao NJ; Horning SJ; Blume KG; Ahn DK; Lamborn KR; Fleming NC; Bonnem EM; Greenberg PL
    Ann Intern Med; 1992 Feb; 116(3):183-9. PubMed ID: 1345803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor.
    Schenkein DP; Koc Y; Alcindor T; Stadtmauer EA; Miller KB; Cooper BW; Partridge AH; Lazarus HM
    Biol Blood Marrow Transplant; 2000; 6(4A):448-55. PubMed ID: 10975514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group Trial.
    Lazarus HM; Andersen J; Chen MG; Variakojis D; Mansour EG; Oette D; Arce CA; Oken MM; Gerson SL
    Blood; 1991 Aug; 78(3):830-7. PubMed ID: 1859894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood progenitor cell harvesting in multiple myeloma and malignant lymphoma.
    Scott MA; Ager S; Apperley JF; Jestice HK; Bloxham DM; Boraks P; Mahendra P; Marcus RE
    Leuk Lymphoma; 1995 Nov; 19(5-6):479-84. PubMed ID: 8590850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.